Skip to content

Framing Messages for Smoking Cessation With Bupropion - 6

Framing Messages for Smoking Cessation With Buproprion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00104598
Enrollment
252
Registered
2005-03-02
Start date
2000-09-30
Completion date
2006-12-31
Last updated
2013-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder

Brief summary

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.

Interventions

DRUGBupropion
BEHAVIORALSmoking Abstinence Program

This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Exclusion criteria

* Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception * Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality * Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment * Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous * Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks * History of anorexia nervosa or bulimia * Previous hypersensitivity to bupropion * History of alcohol or other drug dependence in the past one year * History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.) * Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk * Sharing home or work environment with current or past participant * No couples or participants who see each other every day

Design outcomes

Primary

MeasureTime frameDescription
Smoking Cessation at 7 days7-day point prevalence abstinence
Continuous Smoking Abstinence at 6 weeks6 weeks6-week continuous abstinence.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026